UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Paid-in Capital	Management Notes Receivable	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income
Equity, beginning balance at Dec. 31, 2016	$ 600,770	$ 0	$ 14	$ 0	$ 615,713	$ (1,171)	$ (13,786)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' redemptions	(56)					(56)
Stockholders' redemptions	0				(111)	111
Stock-based incentive compensation	1,455				1,455
Net income (loss)	3,878						3,878
Reclassification of certain tax effects	0						(12)	12
Other comprehensive income	58							58
Equity, ending balance at Dec. 31, 2017	606,105	0	14	0	617,057	(1,116)	(9,920)	70
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	0				425	(425)
Stockholders' redemptions	(78)					(78)
Stock-based incentive compensation	2,139				2,139		0
Net income (loss)	(6,115)						(6,115)
Other comprehensive income	774							774
Equity, ending balance at Dec. 31, 2018	602,825	0	14	0	619,621	(1,619)	(16,035)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Purchase of BioScrip, Inc.	387,044		4		387,040
Stockholders' redemptions	(62)					(62)
Repayment of management notes receivable	1,310					1,310
Stockholders' redemptions	(2,000)				(2,371)	371
Stock-based incentive compensation	4,170				4,170
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(2,501)			(2,403)	(98)
Net income (loss)	(75,920)						(75,920)
Other comprehensive income	(8,039)							(8,039)
Equity, ending balance at Dec. 31, 2019	$ 906,827	$ 0	$ 18	$ (2,403)	$ 1,008,362	$ 0	$ (91,955)	$ (7,195)